BioCentury
ARTICLE | Distillery Therapeutics

Therapeutics: Receptor-interacting serine-threonine kinase 3 (RIPK3; RIP3); mixed-lineage kinase domain-like (MLKL)

March 3, 2016 8:00 AM UTC

Cell and mouse studies suggest inhibiting RIPK3 or MLKL could help treat crystal-induced acute kidney injury (AKI). In mouse kidney epithelial cells, siRNA targeting RIPK3 or MLKL decreased cell death...